Bladder cancer cells on a pink background

2026 ASCO Annual Meeting

Congress coverage by Medthority

Last updated: 3rd Jun 2026

Published: 30th May 2026

Get closer to the conversations set to change clinical practice with our expert-led selection of key highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Find essential insights spanning second-line treatment strategies in small-cell lung cancer (SCLC) and first-line therapeutic options in non–small-cell lung cancer (NSCLC), alongside the latest trial data in bladder and prostate cancer.

ASCO 2026: SCLC highlights

Review key ASCO 2026 findings on intracranial outcomes with tarlatamab, second-line ES-SCLC treatment patterns, and thoracic radiotherapy.

READ NOW

ASCO 2026: EA5142 trial results in resected NSCLC

Check out the phase 3 EA5142 results from ASCO 2026 showing no DFS benefit with adjuvant nivolumab vs observation in resected NSCLC.

READ NOW

ASCO 2026: HARMONi-6 results in first-line NSCLC

Check out phase 3 HARMONi-6 results from ASCO 2026 showing improved overall survival with ivonescimab plus chemotherapy in advanced squamous NSCLC.

READ NOW

ASCO 2026: CROWN study. Lorlatinib in ALK+ NSCLC

Explore 7-year CROWN data from ASCO 2026 showing durable lorlatinib benefit in ALK+ NSCLC, including long-term CNS control and safety outcomes.

READ NOW

ASCO 2026: POTOMAC NMIBC results

Review POTOMAC findings on durvalumab plus BCG in high-risk NMIBC, showing no OS detriment and preserved quality of life.

READ NOW

ASCO 2026: HRQoL data from the KEYNOTE-905 trial

Explore KEYNOTE-905 data showing preserved HRQoL with perioperative EV plus pembrolizumab in cisplatin-ineligible MIBC.

READ NOW

ASCO 2026: ASCO 2026: PROTEUS trial results

View PROTEUS data showing improved MFS and pathological response with perioperative apalutamide plus ADT in high-risk prostate cancer.

READ NOW

ASCO 2026: TALAPRO-3: Talazoparib + enzalutamide in mCSPC

Phase 3 TALAPRO-3 results presented at ASCO 2026 show improved rPFS with talazoparib plus enzalutamide in HRR-altered mCSPC.

READ NOW

Thumbnail of video featuring Bjørn Henning Grønberg

ASCO 2026: Expert interviews

Watch insights from the experts presenting key trial data in lung and prostate cancer over on our YouTube channel.

WATCH NOW

Photo of Prostate cancer cells under microscope, pink and purple tones.

Prostate Cancer Nexus

Congress coverage and expert podcasts

Light microscopy of the internal lining of the urinary bladder; haematoxylin and eosin stain

Managing High-Risk NMIBC

Expert and patient insights on high-risk NMIBC, including relevant clinical trial data and standout congress sessions.

Lung Cancer Nexus

Browse expert insights on lung cancer

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information

Name

Email address

Specialty

By providing your email address, you are opting in to receive our monthly newsletter.

Opt-in: By selecting this box, I consent to receiving marketing communications and information about Medthority's resources by email.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event